Global office locator

Careers in finance look different when you are close to the centre of a global organisation. At ICON’s Dublin headquarters, our finance professionals gain exposure across regions, work closely with senior leaders, and a...

Is AI enough? Artificial intelligence has revolutionised site identification, but it’s not the whole story. At SCOPE 2026, join Travis Caudill, VP – Feasibility, Site Selection & Medical Informatics, as he explores why s...

Long-term follow-up for vaccines may seem to be a distant concern when clinical trials are just beginning, but it can be critical to have a plan for follow-up at the outset. Learn considerations for follow-up design, s...

In 2025 ICON was recognised for its commitment to building an inclusive workplace. Learn more. https://ow.ly/uWXN50XSPUE

At ICON, we understand that exploring a new career opportunity comes with questions. Having a clear sense of what to expect can make the experience feel more straightforward. This week, we’re sharing a five part series ...

The development of longer-acting and more potent NUSH receptor agonists, like semaglutide, has helped clarify the link between aberrant glucose metabolism and a range of diseases. Learn how to embrace the multi-indicatio...

PubsHub Journals & Congresses now includes publication AI policy guidelines, ensuring ethical use and transparency in research. Whether you use AI to analyze data or draft manuscripts, learn what’s required for complianc...

ICON is heading to SCOPE 2026 From labs and patient solutions to site strategies and biosimilars, our experts will be on the ground in Orlando from 2–5 February. We’re ready to share insights on accelerating clinical de...

To unlock the full value of emerging multi-indication therapies, developers must adopt strategies that prioritise early cross-functional planning and innovative trial architecture. ICON’s Jack Martin and Alan Baldridge...

Product labelling and promotional materials are the foundation of pharma communication and effective pharmaceutical communications begin with a strategic vision anchored in the product label. Regulatory change often br...

#OCTWestCoast will be returning to Burlingame for the 18th annual event on 11-12 February. Pass by booth \#79 and engage in an insightful discussion with ICON Biotech’s professionals regarding the latest challenges and s...

In 2025 ICON was independently recognised as a leading CRO for both Ph1 and Ph 2/3 studies and was also awarded Best CRO in APAC. Learn more. https://ow.ly/wfMb50XSPQG